Your fact-checks will appear here
Mammalian protein found in Homo sapiens
Raising ivermectin concentrations in humans can be approached by higher or more frequent oral dosing, formulation and route changes (controlled‑release, parenteral or inhaled delivery), and pharmacoki...
Oral ivermectin is the standard human route and produces moderate systemic bioavailability that is sensitive to formulation and food (notably high-fat meals) and to intestinal metabolism and efflux me...
When patients take multiple prescription drugs, ivermectin dosing is not a one-size-fits-all calculation but a weight-based starting point (typically ~150–200 mcg/kg) that must be reconsidered in ligh...
Ivermectin commonly interacts with drugs that affect CYP3A4 metabolism and P‑glycoprotein (P‑gp) transport, and with substances that add central‑nervous‑system (CNS) depression or alter bleeding risk;...
Ivermectin’s pharmacokinetics are influenced by body composition and age in ways that often affect distribution and timing more than peak systemic exposure, while P‑glycoprotein (P‑gp) activity and CY...
Published measurements of the plasma elimination half‑life of oral ivermectin in adults vary widely, with regulatory labels and some clinical studies reporting about 18 hours while other pharmacokinet...
Known patient factors that raise concern for higher ivermectin exposure or adverse effects include very low body weight (children <15 kg), advanced age with comorbid organ disease, and impaired liver ...